Palabras claves: Alzheimer's disease, neuroprotection, Okadaic acid, PP2A-activating drug (PAD), Protein phosphatase 2A (PP2A), Tauopathies
Autores: Arribas R.L., de los Ríos C., García-Frutos E.M., Isaac Bravo, Janssens V., Martínez M., Montiel C., Ramos E., Romero A., Viejo L.